The trademark application LINXIS was filed by LinXis B.V., a corporation established under the laws of the Kingdom of the Netherlands (the "Applicant"). The application was published for oppositions on September 27, 2020, and it was registered by office on January 7, 2021 without any oppositions.
The application was filed in English (German was selected as the second language).
Goods And Services
The mark was filed in class 1 with following description of goods:
Chemical additives for use in the manufacture of pharmaceuticals
Chemical preparations for use in the manufacture of pharmaceuticals
Active chemical ingredients for use in the manufacture of pharmaceuticals.
The mark was filed in class 5 with following description of goods:
Pharmaceutical drugs
Drug delivery agents
Drugs for medical purposes
Drug delivery agents that facilitate the delivery of pharmaceutical preparations
Biochemical medicines
Chemical preparations for pharmaceutical purposes
Diagnostic agents for pharmaceutical purposes
Pharmaceutical substances and preparations
Carrier excipients for pharmaceutical preparations.
The mark was filed in class 42 with following description of goods:
Pharmaceutical research
Conducting clinical trials for pharmaceuticals
Pharmaceutical research and development
Pharmaceutical product evaluation
Consultancy relating to pharmaceutical research and development
Laboratory research services relating to pharmaceuticals
Providing information about the results of clinical trials for pharmaceuticals
Providing information about medical and scientific research in the field of pharmaceuticals
Research services in the field of proteins, antibodies, microorganisms and cells
Research and development services in the field of antibody technology
Design and development of medical technology.
The mark was filed in class 44 with following description of goods:
In vitro analysis for medical and pharmaceutical use
In vitro testing for medical and pharmaceutical use
Consultancy and information services provided via the Internet relating to pharmaceutical products.